Frigo P, Eppel W, Asseryanis E, Sator M, Golaszewski T, Gruber D, Lang C, Huber J
Department of Gynecology and Obstetrics, Vienna University Hospital, Austria.
Maturitas. 1995 Apr;21(3):221-5. doi: 10.1016/0378-5122(94)00893-c.
The aim of our study was to examine the effects of hormone replacement on the size of the uterus and the development or increase of myomatas. Fifty perimenopausal women were included in the study (53.8 +/- 5.0 years). Patients received a substitution therapy composed of a combination of 4 mg estradiovalerate and 200 mg prasteronenantate (Gynodian Depot cartridges) given as a muscular injection in 6-10 week intervals (mean 7 weeks +/- 4 days). Prior to the onset of therapy with Gynodian and after a period of 12 months (+/- 13 days) vaginosonography was performed. Measurements taken were length, thickness, height of endometrium, size of ovaries and of myomas. Data obtained were correlated with baseline findings. Within 1 year, significant increases in uterus length from 73.4 mm to 88.2 mm, in uterus thickness from 33.9 mm to 43.5 mm and in endometrium height from 4.1 mm to 6.7 mm were observed (median values). There was an increase in both the number (from 2.2 to 3.5) and the size of the myomatas (29.4-35.0 mm diameter). A statistical analysis conducted by means of the Wilcoxon matched pairs signed-rank sum test showed P < 0.001. No significant change occurred in the size of the ovaries. Our study shows that hormone substitution may have an impact on uterus growth and that therefore vaginosonographical monitoring can be recommended.
我们研究的目的是检测激素替代疗法对子宫大小以及肌瘤发生或增大的影响。50名围绝经期女性纳入本研究(年龄53.8±5.0岁)。患者接受由4mg戊酸雌二醇和200mg普瑞睾酮(复方庚酸炔诺酮注射液)组成的替代疗法,每6 - 10周肌肉注射一次(平均7周±4天)。在开始使用复方庚酸炔诺酮治疗前及治疗12个月(±13天)后进行阴道超声检查。测量指标包括子宫内膜的长度、厚度、高度、卵巢大小及肌瘤大小。将获得的数据与基线结果进行相关性分析。1年内观察到子宫长度从73.4mm显著增加至88.2mm,子宫厚度从33.9mm增加至43.5mm,子宫内膜高度从4.1mm增加至6.7mm(中位数)。肌瘤数量(从2.2个增至3.5个)及大小(直径从29.4mm增至35.0mm)均增加。采用Wilcoxon配对符号秩和检验进行统计学分析显示P < 0.001。卵巢大小无显著变化。我们的研究表明激素替代可能对子宫生长有影响,因此推荐进行阴道超声监测。